Zacks Investment Research downgraded shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) from a hold rating to a sell rating in a research report report published on Thursday.

According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

PTGX has been the subject of a number of other reports. BMO Capital Markets began coverage on shares of Protagonist Therapeutics in a report on Tuesday, September 6th. They issued an outperform rating for the company. Leerink Swann began coverage on shares of Protagonist Therapeutics in a report on Tuesday, September 6th. They set an outperform rating and a $17.00 price objective on the stock. Finally, Barclays PLC began coverage on shares of Protagonist Therapeutics in a report on Tuesday, September 6th. They set an overweight rating and a $18.00 price objective on the stock.

Shares of Protagonist Therapeutics (NASDAQ:PTGX) opened at 24.99 on Thursday. The company’s market cap is $417.68 million. Protagonist Therapeutics has a 1-year low of $10.02 and a 1-year high of $25.60. The firm’s 50-day moving average is $22.06 and its 200-day moving average is $18.12.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Monday, November 14th. The company reported ($0.87) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by $0.29. During the same period last year, the company posted ($12.79) EPS.

COPYRIGHT VIOLATION WARNING: This piece of content was first published by Daily Political and is the propert of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The original version of this piece of content can be read at http://www.dailypolitical.com/2016/11/30/protagonist-therapeutics-inc-ptgx-cut-to-sell-at-zacks-investment-research.html.

Institutional investors have recently bought and sold shares of the stock. Credit Suisse AG bought a new position in Protagonist Therapeutics during the third quarter valued at about $358,000. BVF Inc. IL purchased a new stake in shares of Protagonist Therapeutics during the third quarter worth approximately $7,924,000. RA Capital Management LLC purchased a new stake in shares of Protagonist Therapeutics during the third quarter worth approximately $15,941,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Protagonist Therapeutics during the third quarter worth approximately $33,408,000. Finally, Spark Investment Management LLC purchased a new stake in shares of Protagonist Therapeutics during the third quarter worth approximately $889,000.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (Protagonist) is a clinical-stage biopharmaceutical company. The Company has a technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Protagonist’s primary focus is on developing oral peptide drugs that specifically target biological pathways.

5 Day Chart for NASDAQ:PTGX

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Protagonist Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.